Down Syndrome Market Expected to Witness Significant Growth by 2036, Driven by Advancing Therapeutic Research and Increasing Healthcare Investment | DelveInsight

The Down Syndrome market is expected to witness notable growth across the seven major markets (7MM) during the forecast period (2026-2036), driven by increasing disease awareness, improving diagnosis, expanding supportive care, and the anticipated introduction of emerging therapies targeting cognitive impairment and neurodevelopmental deficits. Growing investments in research, coupled with advances in precision medicine and neuroscience, are expected to reshape the future treatment landscape for individuals living with Down syndrome.

DelveInsight's "Down Syndrome Market Insights, Epidemiology, and Market Forecast-2036" report provides a comprehensive assessment of the evolving market by evaluating disease epidemiology, current treatment practices, emerging therapies, market dynamics, competitive landscape, patient journey, pricing trends, reimbursement scenarios, and forecasted market opportunities across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report offers detailed analyses of diagnosed patient populations, market size, therapy uptake, and future commercial opportunities through 2036.
The report further highlights key unmet medical needs, emerging clinical programs, epidemiological trends, and evolving healthcare policies that are expected to influence the Down Syndrome treatment landscape over the coming decade.

To know more about the Down Syndrome market, epidemiology, and forecast, Click here:
https://www.delveinsight.com/sample-request/down-syndrome-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Key Takeaways from the Down Syndrome Market Report

• The Down Syndrome market across the 7MM is projected to experience significant growth during the forecast period (2026-2036), primarily driven by the anticipated launch of emerging therapies, increasing healthcare expenditure, and growing research into cognitive impairment associated with the condition.
• DelveInsight estimates indicate that the Down Syndrome market size is expected to increase from nearly USD 3,726 million in 2022 to approximately USD 5,874 million by 2036 across the seven major markets.
• In 2025, the United States reported the highest diagnosed prevalence, accounting for approximately 315 thousand diagnosed cases, while the 7MM collectively reported nearly 730 thousand diagnosed prevalent cases of Down syndrome.
• Down syndrome comprises three genetic forms-Trisomy 21, Translocation, and Mosaicism-with Trisomy 21 representing the vast majority of diagnosed cases across the major markets.
• According to the report, the 0-9 years age group represents the largest patient population, reflecting the lifelong nature of the condition and the importance of early diagnosis and intervention.
• Although no therapy is currently approved specifically for the treatment of Down syndrome, multiple investigational programs-including AEF0217, ACI-24.060, and CTH120-are advancing clinical development with the goal of improving cognition, adaptive behavior, and neurodevelopmental outcomes.
• In January 2026, Aelis Farma received a positive opinion from the European Medicines Agency Pediatric Committee (PDCO) regarding the Pediatric Investigation Plan (PIP) for AEF0217, supporting its pediatric clinical development program in Down syndrome.

Key Factors Driving the Down Syndrome Market

Growing Diagnosed Patient Population
Improved prenatal screening, enhanced diagnostic capabilities, increasing maternal age, better healthcare access, and longer life expectancy among individuals with Down syndrome are contributing to a steady increase in diagnosed prevalence across the seven major markets. These trends are expected to drive demand for supportive care and future disease-modifying therapies.

Increasing Research into Cognitive Impairment
There is growing scientific interest in addressing cognitive deficits, adaptive behavior, and neurodevelopmental impairment associated with Down syndrome. Advances in neuroscience, molecular biology, and targeted therapeutics have accelerated clinical research aimed at developing disease-specific interventions capable of improving quality of life for affected individuals.

Expanding Pipeline of Novel Therapies

The development pipeline is becoming increasingly active with innovative candidates targeting multiple biological pathways associated with Down syndrome. Emerging therapies such as AEF0217, ACI-24.060, and CTH120 represent novel approaches focused on improving cognition, neuroplasticity, and Alzheimer's disease-related pathology, potentially transforming future treatment paradigms.
Rising Healthcare Investment and Early Intervention Programs

Comprehensive management of Down syndrome increasingly emphasizes multidisciplinary care, including speech therapy, occupational therapy, physical therapy, behavioral interventions, and management of associated comorbidities. Continued investment in early intervention services, specialized healthcare infrastructure, and clinical research is expected to support market expansion throughout the forecast period.

Down Syndrome Market Analysis

Down syndrome remains one of the most common chromosomal disorders worldwide, characterized by intellectual disability, developmental delays, and a broad spectrum of associated medical conditions, including congenital heart disease, hearing impairment, thyroid disorders, gastrointestinal abnormalities, and an increased risk of Alzheimer's disease. While advances in supportive care have significantly improved survival and quality of life, there is currently no approved therapy that directly treats the underlying genetic cause of Down syndrome.

The therapeutic landscape is therefore centered on multidisciplinary care and management of associated comorbidities. Physical therapy, occupational therapy, speech-language therapy, behavioral interventions, surgical correction of congenital abnormalities, and medications addressing associated neurological or medical complications continue to form the foundation of patient management.
Meanwhile, increasing research activity is focused on therapies capable of improving cognition, adaptive behavior, and neurodevelopmental outcomes.

The market is expected to evolve considerably over the coming decade as innovative investigational therapies progress through clinical development. Continued improvements in diagnosis, increasing healthcare awareness, expanding research funding, and growing understanding of Down syndrome biology are anticipated to create meaningful opportunities for pharmaceutical innovation. Although scientific and regulatory challenges remain, the emergence of targeted therapies has the potential to reshape future management strategies and improve long-term outcomes for individuals living with Down syndrome.

Get a Free sample for the Down Syndrome Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/sample-request/down-syndrome-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Down Syndrome Competitive Landscape

The Down Syndrome therapeutic landscape is undergoing gradual but meaningful transformation as biotechnology companies increasingly focus on developing therapies that target cognitive impairment, neurodevelopmental dysfunction, and Alzheimer's disease associated with Down syndrome. Although no therapy is currently approved specifically for the treatment of Down syndrome, advances in neuroscience, receptor modulation, immunotherapy, and neuroplasticity research are creating new opportunities for disease-specific interventions.

Current management primarily relies on multidisciplinary supportive care, including speech-language therapy, occupational therapy, physical therapy, behavioral interventions, and treatment of associated medical conditions such as congenital heart disease, hypothyroidism, hearing impairment, gastrointestinal disorders, epilepsy, and
Down syndrome-associated Alzheimer's disease. As several innovative therapies advance through clinical development, the competitive landscape is expected to become increasingly dynamic during the forecast period.

Emerging Therapies Driving the Down Syndrome Market

AEF0217: Aelis Farma
AEF0217 is a CB1 receptor-specific inhibitor developed by Aelis Farma to target cognitive impairment associated with Down syndrome through modulation of the brain's system. The therapy has demonstrated the ability to reverse cognitive deficits in validated preclinical models of Down syndrome, Fragile X syndrome, and age-related cognitive impairment without detectable behavioral side effects. It is currently being evaluated in Phase IIb clinical trials for Down syndrome.
The clinical development of AEF0217 is supported by funding from the European Union's Horizon 2020 Programme. In January 2026, the European Medicines Agency's Pediatric Committee (PDCO) issued a positive opinion on the Pediatric Investigation Plan (PIP) for AEF0217, strengthening its regulatory pathway and supporting future pediatric clinical development in Europe.

ACI-24.060: AC Immune/Takeda
ACI-24.060 is an investigational anti-amyloid beta (Aβ) active immunotherapy being jointly developed by AC Immune and Takeda Pharmaceutical Company for Alzheimer's disease associated with Down syndrome. The vaccine is designed to generate antibodies against misfolded amyloid-beta species, thereby reducing amyloid plaque accumulation and supporting disease modification.
The therapy is currently in Phase Ib/II clinical development. According to the report, results from a randomized Phase Ib study published in May 2022 demonstrated favorable safety and tolerability, generated immunogenic responses in several participants, and showed measurable effects on Alzheimer's disease biomarkers, supporting continued clinical development.

CTH120: Connecta Therapeutics
CTH120 is a first-in-class small-molecule neuroplasticity modulator being developed by Connecta Therapeutics for neurodevelopmental disorders, including Down syndrome. Developed following the evaluation of more than thirty neuroplasticity-related targets, preclinical studies indicate that CTH120 enhances neuroplasticity while demonstrating potential pro-cognitive and social behavior-modulating effects.

The candidate is currently in the preclinical stage for Down syndrome. In March 2025, Connecta Therapeutics reported positive Phase I results for CTH120 in broader neurodevelopmental research, supporting its continued advancement for disorders including Down syndrome and Fragile X syndrome.

Recent Developments in the Down Syndrome Market

• In January 2026, Aelis Farma received a positive opinion from the European Medicines Agency Pediatric Committee (PDCO) for the Pediatric Investigation Plan (PIP) supporting the development of AEF0217 in Down syndrome.
• In March 2025, Connecta Therapeutics announced positive Phase I results for CTH120, reinforcing the clinical development of its neuroplasticity modulator for Down syndrome and other neurodevelopmental disorders.
• Clinical development of AEF0217 continues to receive support through the European Union Horizon 2020 Programme, reflecting continued investment in innovative therapies targeting cognitive impairment in Down syndrome.
• ACI-24.060 continues clinical evaluation for Alzheimer's disease associated with Down syndrome following encouraging early-stage safety, tolerability, immunogenicity, and biomarker findings.

What is Down Syndrome?

Down syndrome, also known as Trisomy 21, is a lifelong genetic condition caused by the presence of an extra copy of chromosome 21. The disorder disrupts normal development and is characterized by intellectual disability, developmental delay, distinctive physical features, and an increased risk of numerous medical conditions, including congenital heart disease, thyroid disorders, hearing impairment, gastrointestinal abnormalities, and Alzheimer's disease later in life. Down syndrome occurs in three genetic forms: Trisomy 21, Translocation, and Mosaicism, with Trisomy 21 accounting for the vast majority of diagnosed cases.
Although there is currently no cure or approved disease-modifying therapy, comprehensive management through early intervention-including physical therapy, speech-language therapy, occupational therapy, behavioral support, educational services, and treatment of associated medical conditions-can substantially improve functional outcomes and quality of life. Research is increasingly focused on developing therapies that address cognitive impairment and neurodevelopmental deficits associated with the condition.

Down Syndrome Epidemiology Segmentation

The DelveInsight report provides detailed epidemiological assessment of Down syndrome across the seven major markets (2022-2036), segmented into:
• Total Diagnosed Prevalent Cases of Down Syndrome
• Gender-specific Diagnosed Prevalent Cases
• Type-specific Cases (Trisomy 21, Translocation, and Mosaicism)
• Age-specific Diagnosed Prevalent Cases (0-9 years, 10-19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, and ≥60 years)
• Diagnosed Cases by Clinical Manifestations
• Country-specific Epidemiology across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan

Download the report to explore detailed epidemiology trends, emerging therapies, and future commercial opportunities in the Down Syndrome market:
https://www.delveinsight.com/sample-request/down-syndrome-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the Down Syndrome Market Report

• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
• Key Companies: Aelis Farma, AC Immune, Takeda Pharmaceutical Company, Connecta Therapeutics, and other emerging biotechnology companies developing therapies for Down syndrome
• Current Management: Physical therapy, Occupational therapy, Speech-language therapy, Behavioral therapy, Surgical interventions for associated congenital anomalies, and pharmacological management of associated comorbidities including Alzheimer's disease, epilepsy, thyroid disorders, hearing impairment, and gastrointestinal complications
• Emerging Therapies: AEF0217, ACI-24.060, CTH120, and other pipeline candidates under clinical and preclinical development
• Patient Segmentation: Type-specific (Trisomy 21, Translocation, Mosaicism), Gender-specific, Age-specific, Clinical Manifestations, and Country-specific epidemiology across the 7MM
• Market Dynamics: Market Drivers, Barriers, Opportunities, Unmet Needs, SWOT Analysis, Competitive Intelligence, Pricing Trends, Analogue Analysis, and Future Market Opportunities
• Market Access & Reimbursement: Country-specific reimbursement and Health Technology Assessment (HTA) landscape across the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan
• Additional Coverage: Patient Journey, Key Opinion Leader (KOL) Insights, Therapy Uptake Analysis, Market Forecasts, and Analyst Perspectives

To learn more about the Down Syndrome market, emerging therapies, and future commercial opportunities, visit:
https://www.delveinsight.com/sample-request/down-syndrome-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

• Down Syndrome Market Report Introduction
• Down Syndrome Market Executive Summary
• Down Syndrome Market Overview
• Down Syndrome Epidemiology Analysis
• Down Syndrome Patient Journey
• Down Syndrome Treatment Landscape
• Down Syndrome Market Dynamics
• Down Syndrome Market Size and Forecast (2022-2036)
• Emerging Therapies for Down Syndrome
• Competitive Landscape
• Key Companies
• Key Emerging Therapies
• Epidemiology Segmentation
• Market Access and Reimbursement
• Pricing and Analogue Analysis
• Key Opinion Leaders' Views
• Unmet Needs
• SWOT Analysis
• Market Drivers and Barriers
• Future Perspectives
• Analyst Views
• Appendix

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.